CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Accelerate PhenoTest™ BC Kit +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03218397
NCT03218397N/ACompleted
CompareCT.gov

Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)

Duke University·interventional·Posted Jul 14, 2017·Updated Nov 26, 2019

In Brief

A clinical study evaluating Accelerate PhenoTest™ BC Kit and Standard Culture and AST for Gram-negative Bacteremia. Completed, enrolled 500 participants across 2 sites.

Detailed Summary

RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1. Standard culture and antimicrobial susceptibility testing (AST); or 2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGram-negative Bacteremia
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 14, 2017
Enrollment StartOct 9, 2017
Primary CompletionNov 3, 2018
Study CompletionNov 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.0 years ago

Interventions

Accelerate PhenoTest™ BC Kitdevice

Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)

Standard Culture and ASTdevice

Standard culture and antimicrobial susceptibility testing (AST)